6,7-difluoro-2-(4-((1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 6,7-difluoro-2-(4-((1-(1-(tetrahydro-2H-pyran-4-yl)ethyl)-1H-imidazol-5-yl)methyl)piperazin-1-yl)benzo[d]oxazole
• 英文别名: 6,7-Difluoro-2-[4-[[3-[1-(oxan-4-yl)ethyl]imidazol-4-yl]methyl]piperazin-1-yl]-1,3-benzoxazole；6,7-difluoro-2-[4-[[3-[1-(oxan-4-yl)ethyl]imidazol-4-yl]methyl]piperazin-1-yl]-1,3-benzoxazole
• 化学式: C₂₂H₂₇F₂N₅O₂
• 分子量: 431.485
• InChiKey: RBUZFCPEIYQFNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  31
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  59.6
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• [EN] PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG<br/>[FR] DÉRIVÉS D'IMIDAZOLE ET DE TRIAZOLE LIÉS À LA PIPÉRIDINE OU LA PIPÉRAZINE ET LEURS PROCÉDÉS D'UTILISATION POUR AMÉLIORER LA PHARMACOCINÉTIQUE D'UN MÉDICAMENT
  申请人：MERCK SHARP & DOHME

  公开号：WO2015070367A1

  公开（公告）日：2015-05-21

  The piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug are provided. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

  提供了与哌啶或哌嗪连接的咪唑和三唑衍生物，包括所述化合物的组合物，单独或与其他药物结合使用的方法，以及用于改善药物的药代动力学的化合物的方法。该发明的化合物在人类和兽医学中用于抑制CYP3A4并改善由CYP3A4代谢的治疗化合物的药代动力学。
• [EN] PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG<br/>[FR] DÉRIVÉS DE TRIAZOLE ET D'IMIDAZOLE À LIAISON PIPÉRIDINE OU PIPÉRAZINE ET LEURS PROCÉDÉS D'UTILISATION POUR AMÉLIORER LA PHARMACOCINÉTIQUE D'UN MÉDICAMENT
  申请人：MERCK SHARP & DOHME

  公开号：WO2015073310A1

  公开（公告）日：2015-05-21

  The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhbiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

  本发明涉及哌啶或哌嗪连接的咪唑和三唑衍生物，包含所述化合物的组合物，单独或与其他药物结合使用的方法，以及用于改善药物的药代动力学的化合物的方法。本发明的化合物在人类和兽医医学中用于抑制CYP3A4并改善由CYP3A4代谢的治疗化合物的药代动力学。
• Piperidine or piperazine linked imidazole and triazole derivatives and methods of use
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US10745377B2

  公开（公告）日：2020-08-18

  The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.

  本发明涉及哌啶或哌嗪连接的咪唑和三唑衍生物、包含上述化合物（单独或与其他药物结合）的组合物，以及使用这些化合物改善药物药代动力学的方法。本发明的化合物可用于人类和兽医领域，抑制 CYP3A4，改善经 CYP3A4 代谢的治疗化合物的药代动力学。
• 1-(ALPHA-METHYLBENZYL)-5-(PIPERIDINOMETHYL)IMIDAZOLE DERIVATIVES AND USES THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
  申请人：MERCK SHARP & DOHME CORP.

  公开号：EP3587411B1

  公开（公告）日：2021-01-27
• PIPERIDINE OR PIPERAZINE LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG
  申请人：Coburn Craig A.

  公开号：US20160297792A1

  公开（公告）日：2016-10-13

  The present invention relates to piperidine or piperazine linked imidazole and triazole derivatives, compositions comprising said compounds, alone or in combination with other drugs, and methods of using the compounds for improving the pharmacokinetics of a drug. The compounds of the invention are useful in human and veterinary medicine for inhibiting CYP3A4 and for improving the pharmacokinetics of a therapeutic compound that is metabolized by CYP3A4.